Microbot Medical Inc. (NASDAQ:MBOT) Stock Has Consensus Price Target of $6.38

Posted by George Bondi on Oct 25th, 2026

Shares of Microbot Medical Inc. (NASDAQ:MBOT – Get Free Report) have been given an average rating of “Moderate Buy” by the seven research firms that are currently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $5.08.

Several brokerages have weighed in on MBOT. Citizens Jmp began coverage on shares of Microbot Medical in a research note on Friday. They issued a “market outperform” rating and a $2.50 target price for the company. B. Riley Financial started coverage on Microbot Medical in a research report on Friday, September 11th. They set a “buy” rating and a $4.00 target price on the stock. Citigroup initiated coverage on Microbot Medical in a report on Friday. They issued a “market outperform” rating for the company. UBS Group set a $2.50 target price on shares of Microbot Medical in a research report on Friday. Finally, Wall Street Zen lowered Microbot Medical from a “sell” rating to a “strong sell” rating in a research report on Saturday.

Check Out Our Latest Stock Analysis on MBOT

Microbot Medical Price Performance

NASDAQ MBOT opened at $0.97 on Friday. The business has a 50 day simple moving average of $1.29 and a two-hundred day simple moving average of $1.71. The stock has a market capitalization of $65.41 million, a PE ratio of -4.06 and a beta of 1.05. Microbot Medical has a 1-year low of $0.93 and a 1-year high of $2.85.

Microbot Medical (NASDAQ:MBOT – Get Free Report) last posted its quarterly earnings data on Tuesday, August 11th. The biotechnology company reported ($0.08) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.08). The firm had revenue of $0.24 million for the quarter, compared to the consensus estimate of $0.13 million. On average, analysts anticipate that Microbot Medical will post -0.30 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. CTC Alternative Strategies Ltd. acquired a new position in shares of Microbot Medical during the 1st quarter worth approximately $28,000. Bank of America Corp DE increased its stake in Microbot Medical by 1,688.1% during the 1st quarter. Bank of America Corp DE now owns 75,799 shares of the biotechnology company’s stock worth $183,000 after buying an additional 71,560 shares during the period. Cetera Investment Advisers raised its holdings in Microbot Medical by 44.7% in the first quarter. Cetera Investment Advisers now owns 42,412 shares of the biotechnology company’s stock valued at $102,000 after acquiring an additional 13,099 shares in the last quarter. Private Advisor Group LLC bought a new position in Microbot Medical during the 1st quarter worth approximately $54,000. Finally, Caitong International Asset Management Co. Ltd acquired a new stake in Microbot Medical during the fourth quarter worth about $65,000. 16.30% of the stock is owned by hedge funds and other institutional investors.

About Microbot Medical

(Get Free Report)

Microbot Medical Inc (NASDAQ: MBOT) is a medical-device company developing robotic technologies for minimally invasive vascular procedures. Its systems are designed to help physicians remotely control guidewires and catheters during endovascular interventions, with the potential to improve procedural control and reduce clinicians’ exposure to radiation.

The company’s primary product candidate is the LIBERTY Endovascular Robotic System, a compact, single-use robotic platform intended to support peripheral and neurovascular procedures.